Armata says inhaled phage candidate AP-PA02 completes Phase 2 trials in cystic fibrosis, bronchiectasis patients

Reuters2026/09/03 11:02

By:Reuters

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Armata Pharmaceuticals disclosed a peer-reviewed publication on Sept. 3, 2026, tied to its AP-PA02 inhaled bacteriophage program.
Results were already presented in the paper, detailing how a key Pseudomonas-targeting phage stays stable pre-infection, then delivers its genome efficiently.
Findings aim to support next-generation antibacterial development, reinforcing the program’s rationale following completed Phase 2 studies in CF, NCFB patients.
Work also signals expansion of the company’s structural biology efforts to proprietary Staphylococcus aureus phages.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Armata Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202609030700PR_NEWS_USPR_____LA39932) on September 03, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Armata says inhaled phage candidate AP-PA02 completes Phase 2 trials in cystic fibrosis, bronchiectasis patients

You may also like

Crypto prices